Systems and methods for controlling inflammatory response
View Patent ↗A method and system for controlling inflammatory response at an internal tissue site of a patient utilizes a reduced-pressure treatment device. Controlling the inflammatory response may be accomplished in a number of ways that involve treating the inflammatory milieu. Treating the inflammatory milieu may include removing or moderating pro-inflammatory stimuli, e.g., fluids, enhancing perfusion of the tissue at or near the internal tissue site, or providing reduced-pressure therapy. The reduced-pressure treatment device is placed at or near the internal tissue site and is fluidly coupled to an external reduced-pressure source. The reduced-pressure treatment device provides reduced pressure proximate the tissue site and treats the inflammatory milieu. The reduced-pressure treatment device for controlling inflammatory response may be a minimally-invasive treatment device.
1. A system for controlling inflammatory response at an internal tissue site of a patient, the system comprising:
a reduced-pressure treatment device configured for deploying in an abdominal cavity interior to the patient's peritoneum proximate the internal tissue site, the reduced-pressure treatment device consisting essentially of a first leg manifold member and a second leg manifold member fluidly coupled to the first leg manifold member, and
an encapsulating envelope formed with fenestrations and enveloping the first leg manifold member and the second leg manifold member;
an external reduced-pressure source for supplying reduced pressure to the reduced-pressure treatment device; a reduced-pressure delivery conduit for fluidly coupling the reduced-pressure source and the reduced-pressure treatment device; and
wherein the reduced-pressure source, reduced-pressure delivery conduit, and reduced-pressure treatment device are operable to provide reduced pressure to the internal tissue site to moderate pro-inflammatory stimuli in order to control systemic inflammatory response throughout the patient's body;
the first leg manifold member and the second leg manifold member intersect to form a central connection site; and
the encapsulating envelope forms an exterior layer over the first leg manifold member, the second leg manifold member, and the central connection site; and
the first leg manifold member and second leg manifold member form two obtuse angles and two acute angles.
2. The system for controlling inflammatory response of claim 1 , wherein the first leg manifold member and the second leg manifold member have an aspect ratio greater than 3.0.
3. The system for controlling inflammatory response of claim 2 , wherein the aspect ratio is greater than 4.0.
4. The system for controlling inflammatory response of claim 2 , wherein the aspect ratio is greater than 5.0.
5. The system of claim 1 , further comprising a sealing member adapted to be placed over the reduced-pressure treatment device and the internal tissue site.
6. The system of claim 5 , wherein at least a portion of the sealing member is further adapted to form at least a portion of the encapsulating envelope.
7. The system of claim 5 , further comprising a manifold adapted to be positioned between the sealing member and the reduced-pressure treatment device and to distribute reduced pressure to the reduced-pressure treatment device.
8. The system of claim 1 , wherein the first leg manifold member and the second leg manifold member each comprise at least two leg modules and a manipulation zone positioned between the leg modules.
9. The system of claim 1 , further comprising a connection member coupled to the first encapsulated leg member and the second encapsulated leg member.